View the Inspirational Notes published in this journal

Exclusively focused on translational aspects of drug delivery, this journal provides a unique forum for publication of high-quality research.

Profiles of our editorial board

Drug Delivery and Translational Research publishes research focused on such topics as designing and developing novel drug delivery systems, with a focus on their application to disease conditions; preclinical and clinical data related to drug delivery systems; short-term and long-term biocompatibility of drug delivery systems, host response; biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; image-guided drug therapy; nanomedicine; devices for drug delivery and drug/device combination products.

In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to activities of the Controlled Release Society.

Drug Delivery and Translational Research publishes six issues a year.

  • Accepted by ISI in SCIE, Biosis Previews and Biological Abstracts
  • Explores the effect in different disease conditions of rationally developed, effective delivery systems
  • Focuses on high-quality research on the development of novel drug delivery systems
  • Presents full-length papers, communications, and reviews, editorials and more

Journal information

Editor-in-Chief
  • Maria Jose Alonso
Publishing model
Hybrid (Transformative Journal). How to publish with us, including Open Access

Journal metrics

4.617 (2020)
Impact factor
4.486 (2020)
Five year impact factor
30 days
Submission to first decision (Median)
359,358 (2021)
Downloads

Latest articles

Journal updates

  • New Inspirational Note recently published: Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm

    New Content ItemThe newly published Inspirational Note features innovative drug delivery technology that replicates the physiological cortisol diurnal rhythm for chronotherapy.

  • Featured Article: July 2022

    Read the featured article from the July 2022 issue!

    New Content Item

    Summary: This study introduces novel theranostic dual-targeting self-assembled peptide nanoparticles incorporated with NIRF dye and gamma-emitting radionuclide for dual-imaging functionality and enhanced therapeutic efficacy. The efficient tumor tissue targeting potential of these peptide nanoparticles was validated by the markedly enhanced therapeutic efficacy as compared to other peptide analogs reported in the literature. In vivo SPECT/NIRF images from tumor-bearing animals revealed that these nanoparticles can prominently differentiate the cancer cells from non-cancerous cells and effectively induce cell apoptosis in the targeted tumor tissues. Furthermore, in vivo therapeutic study illustrated drastic decease of tumor volume by these self-assembled peptide nanoparticles in a subcutaneous mouse model of glioblastoma.

  • Featured Article: June 2022

    Read the featured article from the June 2022 issue!

    New Content Item

    Summary: The goal of the current research was to develop an ImM (tyrosine kinase inhibitor) containing nanoformulation and to determine if kidney delivery could be improved over traditional ImM in order to potentially treat nephritis secondary to systemic lupus erythematosus (SLEN).  The glomerulus is the location within the kidney targeted in SLEN.  A fish oil–based ImM oil-in-water nanoemulsion was developed and characterized for particle size, zeta potential, pH, and stability.  MRL/MpJ-Faslpr (a mouse model of SLEN) and control mice (MRL-MpJ) were employed.  The nanoemulsion characteristics were favorable for renal deposition (60-80 nm size, zeta potential of −6.6 to −7.8 mV, polydispersity index < 0.3, 3-day stability at 4 °C) and demonstrated limited leakage.  Kidney deposition of ImM was found to be threefold higher in mice that received the nanoformulation versus naked formulation. Future strategies will define dose-efficacy and dose-toxicity relationships, and characterize and evaluate approaches to further enhance kidney deposition.

    The Editorial Board of DDTR selected this article as the best paper of this issue. 

  • Featured Article: May 2022

    Read the featured article from the May 2022 issue!

    New Content Item

    Summary: This study compared drug delivery, pharmacokinetics, and treatment response after doxorubicin (DOX) conventional (c-) versus drug-eluting embolic (DEE-) transarterial chemoembolization (TACE) in a rabbit VX2 liver tumor model. Twenty-four liver tumors underwent c-TACE (n=12) or DEE-TACE (n=12). Systemic, intra-tumoral, and liver DOX levels were measured using mass spectrometry. Intra-tumoral DOX was quantified using fluorescence imaging. Percent tumor necrosis was assessed. Peak DOX concentration (µg/mL) for plasma, tumor, and liver were 0.666, 4.232, 0.270 for c-TACE, versus 0.103, 8.988, 0.610 for DEE-TACE. Area under the concentration versus time curve (µg/mL*min) for plasma, tumor tissue, and liver were 18.3, 27,078.8, 1,339.1 for c-TACE versus 16.4, 26,204.8, 1,969.6 for DEE-TACE. c-TACE achieved higher DOX coverage of tumor vs. DEE-TACE (10.8% vs. 2.3%; P=0.003). Percent tumor necrosis was similar (39% vs. 37%; P=0.806). In conclusion, in a preclinical model, both c-TACE and DEE-TACE achieved tumoricidal intra-tumoral DOX levels, though c-TACE resulted in greater tumor coverage.

    The Editorial Board of DDTR selected this article as the best paper of this issue. 

View all updates

Societies, partners and affiliations

About this journal

Electronic ISSN
2190-3948
Print ISSN
2190-393X
Abstracted and indexed in
  1. Baidu
  2. CLOCKSS
  3. CNKI
  4. CNPIEC
  5. Chemical Abstracts Service (CAS)
  6. Dimensions
  7. EBSCO Discovery Service
  8. EMBASE
  9. Google Scholar
  10. Japanese Science and Technology Agency (JST)
  11. Journal Citation Reports/Science Edition
  12. Medline
  13. Meta
  14. Naver
  15. Norwegian Register for Scientific Journals and Series
  16. OCLC WorldCat Discovery Service
  17. Portico
  18. ProQuest-ExLibris Primo
  19. ProQuest-ExLibris Summon
  20. Reaxys
  21. SCImago
  22. SCOPUS
  23. Science Citation Index Expanded (SCIE)
  24. TD Net Discovery Service
  25. UGC-CARE List (India)
  26. Wanfang
Copyright information

Rights and permissions

Springer policies

© Controlled Release Society